Cormorant Asset Management Increases Alumis Stake to 4.37%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 17 2026
0mins
Source: Fool
- Increased Holdings: Cormorant Asset Management disclosed a purchase of 313,645 shares of Alumis in Q1 2026, with an estimated transaction value of $7.84 million, indicating strong confidence in the company's growth prospects.
- Value Appreciation: By quarter-end, the value of Alumis' stake rose by $51.52 million due to market price movements, reflecting investor enthusiasm for its biopharmaceutical products targeting autoimmune diseases.
- Outstanding Market Performance: Alumis shares surged approximately 400% over the past year, significantly outperforming the S&P 500's 25% gain, highlighting positive market expectations for its clinical-stage pipeline.
- Financial Flexibility: As of March 31, Alumis reported about $569.5 million in cash and cash equivalents, which is expected to fund operations into late 2027, enhancing its competitive position in the biopharmaceutical sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALMS
Wall Street analysts forecast ALMS stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 23.050
Low
32.00
Averages
37.57
High
50.00
Current: 23.050
Low
32.00
Averages
37.57
High
50.00
About ALMS
Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of envudeucitinib for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biotech Company Movements Analysis
- TherapeuticsMD Strategic Review: TherapeuticsMD (TXMD) saw its shares soar over 20% as the company evaluates various strategic alternatives including acquisitions and mergers, with Q1 net income reaching $103,000, a significant turnaround from a $636,000 loss last year, indicating potential for transformation.
- Sensei Biotherapeutics Clinical Progress: Sensei Biotherapeutics (SNSE) experienced a 20.48% stock increase driven by optimism surrounding its key clinical trial; the drug PIKTOR is currently in a Phase 1b/2 trial for HR+/HER2- breast cancer, with interim data expected in 2027, which could present significant market opportunities.
- Shattuck Labs Crohn's Disease Trial: Shattuck Labs (STTK) shares rose 18% as its candidate SL-325 demonstrated safety in a Phase 1 trial, with plans to initiate a Phase 2 trial for Crohn's disease in Q3 2026, potentially opening new treatment avenues for the company.
- Alumis NDA Submission Progress: Alumis (ALMS) saw a 15.55% increase in stock price, with its lead drug Envudeucitinib undergoing a pivotal Phase 2b study for systemic lupus erythematosus, and an NDA submission expected in Q4 2026, marking a significant advancement in the treatment of immune-mediated diseases.
See More
Deep Track Capital Acquires Significant Stake in Alumis
- Stake Acquisition: Deep Track Capital disclosed a purchase of 6,772,595 shares of Alumis in Q1 2026, valued at approximately $169.31 million, indicating strong confidence in the company's future potential.
- Stock Performance: As of May 15, Alumis shares were priced at $22.02, reflecting a remarkable 355% increase over the past year, significantly outperforming the S&P 500's 28% rise during the same period, showcasing market optimism regarding its biopharmaceutical products.
- Financial Position: Alumis reported a market capitalization of $2.8 billion and a trailing twelve-month revenue of $8.40 million, with a net loss of $237.41 million; however, its $569.5 million in cash and equivalents provides substantial funding for future R&D initiatives.
- Product Development Outlook: Alumis is focused on its TYK2 inhibitor envudeucitinib, with recent clinical trial results demonstrating efficacy in treating psoriasis, and plans to submit a New Drug Application in Q4 2026, potentially unlocking significant market opportunities for the company.
See More
Deep Track Capital Acquires Significant Stake in Alumis
- Stake Acquisition: Deep Track Capital acquired 6,772,595 shares of Alumis in Q1 2026, with an estimated transaction value of $169.31 million, reflecting its ongoing confidence in the biotechnology sector.
- Asset Management Impact: This transaction increased Deep Track's position value in Alumis by $149.20 million, indicating a 2.76% growth in its reportable assets under management, further solidifying its standing in healthcare investments.
- R&D Potential: Alumis focuses on innovative therapies for autoimmune and neuroinflammatory diseases, particularly its TYK2 inhibitor envudeucitinib, which demonstrated a 68% PASI 90 response rate in clinical trials, with a new drug application expected in Q4 2026, potentially disrupting the market.
- Financial Health: As of Q1 2026, Alumis reported $569.5 million in cash and cash equivalents, expected to fund operations into Q4 2027, suggesting that if upcoming data performs well, the current valuation may appear conservative.
See More
Cormorant Asset Management Increases Alumis Stake to 4.37%
- Increased Holdings: Cormorant Asset Management disclosed a purchase of 313,645 shares of Alumis in Q1 2026, with an estimated transaction value of $7.84 million, indicating strong confidence in the company's growth prospects.
- Value Appreciation: By quarter-end, the value of Alumis' stake rose by $51.52 million due to market price movements, reflecting investor enthusiasm for its biopharmaceutical products targeting autoimmune diseases.
- Outstanding Market Performance: Alumis shares surged approximately 400% over the past year, significantly outperforming the S&P 500's 25% gain, highlighting positive market expectations for its clinical-stage pipeline.
- Financial Flexibility: As of March 31, Alumis reported about $569.5 million in cash and cash equivalents, which is expected to fund operations into late 2027, enhancing its competitive position in the biopharmaceutical sector.
See More
Omega Fund Management Reduces Alumis Stake
- Share Reduction Details: Omega Fund Management disclosed a reduction of 411,968 shares in Alumis during Q1 2026, with an estimated transaction value of $10.3 million, indicating a potential decrease in confidence despite retaining 241,255 shares, which remain significant in their biotech-heavy portfolio.
- Market Performance Analysis: Alumis shares are priced at $22.87, reflecting a remarkable 327% increase over the past year, significantly outperforming the S&P 500's roughly 25% gain, suggesting strong market recognition of its clinical-stage therapies, although Omega's sale may impact short-term investor sentiment.
- Financial Overview: Alumis reported $24.05 million in revenue and a net loss of $243.33 million, yet ended the quarter with $569.5 million in cash and marketable securities, which management asserts will fund operations into late 2027, highlighting ongoing investment in R&D despite substantial losses.
- Clinical Progress and Outlook: Alumis's lead TYK2 inhibitor, envudeucitinib, demonstrated over 60% PASI 90 response rates in late-stage psoriasis trials, with plans for an FDA submission in Q4, emphasizing the critical need for differentiation in the increasingly crowded autoimmune treatment market.
See More
Healthcare Stocks Decline on Friday Afternoon
- Healthcare Index Decline: The NYSE Healthcare Index fell by 0.9% on Friday afternoon, reflecting growing concerns in the market regarding the healthcare sector, which could impact investor confidence and lead to capital outflows from this segment.
- Market Reaction: The overall decline in healthcare stocks may be linked to economic data or policy changes, prompting investors to monitor future market dynamics to assess the long-term implications for the healthcare industry.
- Investor Sentiment: As healthcare stocks decline, investors may reassess their portfolios, particularly in the context of increasing economic uncertainty, potentially leading to a shift of funds towards other sectors.
- Industry Outlook: Short-term volatility in the healthcare sector could affect companies' financing capabilities and R&D investments, thereby impacting future innovation and market competitiveness.
See More
Biotech Company Movements Analysis
- TherapeuticsMD Strategic Review: TherapeuticsMD (TXMD) saw its shares soar over 20% as the company evaluates various strategic alternatives including acquisitions and mergers, with Q1 net income reaching $103,000, a significant turnaround from a $636,000 loss last year, indicating potential for transformation.
- Sensei Biotherapeutics Clinical Progress: Sensei Biotherapeutics (SNSE) experienced a 20.48% stock increase driven by optimism surrounding its key clinical trial; the drug PIKTOR is currently in a Phase 1b/2 trial for HR+/HER2- breast cancer, with interim data expected in 2027, which could present significant market opportunities.
- Shattuck Labs Crohn's Disease Trial: Shattuck Labs (STTK) shares rose 18% as its candidate SL-325 demonstrated safety in a Phase 1 trial, with plans to initiate a Phase 2 trial for Crohn's disease in Q3 2026, potentially opening new treatment avenues for the company.
- Alumis NDA Submission Progress: Alumis (ALMS) saw a 15.55% increase in stock price, with its lead drug Envudeucitinib undergoing a pivotal Phase 2b study for systemic lupus erythematosus, and an NDA submission expected in Q4 2026, marking a significant advancement in the treatment of immune-mediated diseases.
See More
Deep Track Capital Acquires Significant Stake in Alumis
- Stake Acquisition: Deep Track Capital disclosed a purchase of 6,772,595 shares of Alumis in Q1 2026, valued at approximately $169.31 million, indicating strong confidence in the company's future potential.
- Stock Performance: As of May 15, Alumis shares were priced at $22.02, reflecting a remarkable 355% increase over the past year, significantly outperforming the S&P 500's 28% rise during the same period, showcasing market optimism regarding its biopharmaceutical products.
- Financial Position: Alumis reported a market capitalization of $2.8 billion and a trailing twelve-month revenue of $8.40 million, with a net loss of $237.41 million; however, its $569.5 million in cash and equivalents provides substantial funding for future R&D initiatives.
- Product Development Outlook: Alumis is focused on its TYK2 inhibitor envudeucitinib, with recent clinical trial results demonstrating efficacy in treating psoriasis, and plans to submit a New Drug Application in Q4 2026, potentially unlocking significant market opportunities for the company.
See More
Deep Track Capital Acquires Significant Stake in Alumis
- Stake Acquisition: Deep Track Capital acquired 6,772,595 shares of Alumis in Q1 2026, with an estimated transaction value of $169.31 million, reflecting its ongoing confidence in the biotechnology sector.
- Asset Management Impact: This transaction increased Deep Track's position value in Alumis by $149.20 million, indicating a 2.76% growth in its reportable assets under management, further solidifying its standing in healthcare investments.
- R&D Potential: Alumis focuses on innovative therapies for autoimmune and neuroinflammatory diseases, particularly its TYK2 inhibitor envudeucitinib, which demonstrated a 68% PASI 90 response rate in clinical trials, with a new drug application expected in Q4 2026, potentially disrupting the market.
- Financial Health: As of Q1 2026, Alumis reported $569.5 million in cash and cash equivalents, expected to fund operations into Q4 2027, suggesting that if upcoming data performs well, the current valuation may appear conservative.
See More
Cormorant Asset Management Increases Alumis Stake to 4.37%
- Increased Holdings: Cormorant Asset Management disclosed a purchase of 313,645 shares of Alumis in Q1 2026, with an estimated transaction value of $7.84 million, indicating strong confidence in the company's growth prospects.
- Value Appreciation: By quarter-end, the value of Alumis' stake rose by $51.52 million due to market price movements, reflecting investor enthusiasm for its biopharmaceutical products targeting autoimmune diseases.
- Outstanding Market Performance: Alumis shares surged approximately 400% over the past year, significantly outperforming the S&P 500's 25% gain, highlighting positive market expectations for its clinical-stage pipeline.
- Financial Flexibility: As of March 31, Alumis reported about $569.5 million in cash and cash equivalents, which is expected to fund operations into late 2027, enhancing its competitive position in the biopharmaceutical sector.
See More
Omega Fund Management Reduces Alumis Stake
- Share Reduction Details: Omega Fund Management disclosed a reduction of 411,968 shares in Alumis during Q1 2026, with an estimated transaction value of $10.3 million, indicating a potential decrease in confidence despite retaining 241,255 shares, which remain significant in their biotech-heavy portfolio.
- Market Performance Analysis: Alumis shares are priced at $22.87, reflecting a remarkable 327% increase over the past year, significantly outperforming the S&P 500's roughly 25% gain, suggesting strong market recognition of its clinical-stage therapies, although Omega's sale may impact short-term investor sentiment.
- Financial Overview: Alumis reported $24.05 million in revenue and a net loss of $243.33 million, yet ended the quarter with $569.5 million in cash and marketable securities, which management asserts will fund operations into late 2027, highlighting ongoing investment in R&D despite substantial losses.
- Clinical Progress and Outlook: Alumis's lead TYK2 inhibitor, envudeucitinib, demonstrated over 60% PASI 90 response rates in late-stage psoriasis trials, with plans for an FDA submission in Q4, emphasizing the critical need for differentiation in the increasingly crowded autoimmune treatment market.
See More
Healthcare Stocks Decline on Friday Afternoon
- Healthcare Index Decline: The NYSE Healthcare Index fell by 0.9% on Friday afternoon, reflecting growing concerns in the market regarding the healthcare sector, which could impact investor confidence and lead to capital outflows from this segment.
- Market Reaction: The overall decline in healthcare stocks may be linked to economic data or policy changes, prompting investors to monitor future market dynamics to assess the long-term implications for the healthcare industry.
- Investor Sentiment: As healthcare stocks decline, investors may reassess their portfolios, particularly in the context of increasing economic uncertainty, potentially leading to a shift of funds towards other sectors.
- Industry Outlook: Short-term volatility in the healthcare sector could affect companies' financing capabilities and R&D investments, thereby impacting future innovation and market competitiveness.
See More
